Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. January 6, 2025. 2025年1月6日 Minaris Regeneraive Medicine株式会社 代表取締役社長 坂東 博人 レゾナックからAltarisへのMinaris株式譲渡完了について Altaris, LLC（以下 Altarisという）は2025年1月6日に株式会社レゾナック・ホールディングス（以下「レゾナック」という）の子会社であるMinaris Regenerative Medicine （米国のMinaris Regenerative Medicine, LLC、日本のMinaris Regenerative Medicine株式会社、ドイツのMinaris Regenerative Medicine ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. January 6, 2025 Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it completed the acquisition of Minaris Regenerative Medicine (Minaris Regenerative Medicine, LLC in the United States, Minaris Regenerative Medicine Co., Ltd. in Japan, Minaris Regenerative Medicine GmbH in Germany, and along with ...
Allendale, NJ, USA and Taipei, Taiwan – October 2, 2024 Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) mainly in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing the one-stop-shop solutions. The strategic partnership ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. 2024年9月24日 Minaris Regeneraive Medicine株式会社 代表取締役社長 坂東 博人 Minarisグループに関する株式譲渡契約締結について 本日2024年9月24日付にて株式会社レゾナック・ホールディングスの連結子会社である株式会社レゾナックは、Minaris Regenerative Medicine株式会社、Minaris Regenerative Medicine, LLC（アメリカ）、及びMinaris Regenerative Medicine GmbH（ドイツ）（以下、3社を総称してMinarisグループ、取締役兼CEO坂東 ...
Yokohama, Japan, Munich, Germany, and Allendale, New Jersey, USA. September 24, 2024. Minaris Regenerative Medicine (“Minaris”), a leading cell therapy contract development and manufacturing organization, is pleased to announce that its parent company, Resonac Corporation (“Resonac”), has entered into a definitive agreement to sell Minaris to a fund managed by Altaris, LLC (collectively with its ...
Yokohama, Japan, München, Deutschland und Allendale, New Jersey, USA. 24. September 2024. Minaris Regenerative Medicine (Minaris), ein führendes Auftragsentwicklungs- und Herstellungsunternehmen (CDMO) für Zelltherapien, freut sich bekanntzugeben, dass seine Mutterfirma, Resonac Corporation („Resonac“), eine endgültige Vereinbarung abgeschlossen hat über den Verkauf von Minaris an einen Fond, der ...
Yokohama, Japan - September 12th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. has been selected for the project publicly solicited by the Japanese organization New Energy and Industrial Technology Development Organization (NEDO). Details in Japanese for local news in Japan. ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - Celltech Innovation Venture Studio Co., Ltd. (“CellTech Accelerator”), the first cell and gene therapy accelerator in Asia, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to accelerate the ...
Taipei, Taiwan, and Yokohama, Japan - August 21st, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cell tech Innovation Venture Studio Co., Ltd. have entered into a business alliance. Details in Japanese for local news in Japan. Celltech Innovation Venture Studio Co., Ltd.（本社：台北、Founder & Chairman Johnny Yu、以下CellTech Accelerator）とMinaris Regenerative ...